Ama Umesi

Banjul, B, GM 
Banjul, B, GM 

Overview

Ama Umesi practices practicing medicine in Banjul, Gambia.

Her clinical expertise encompasses Togaviridae Disease, Poliomyelitis, Myelitis, and Bullae.

She is actively involved in clinical research, co-authoring 8 peer reviewed articles and participating in 1 clinical trial.

Gender

Female

Locations

Banjul, B, Gambia
Other Locations
Fajara, B, Gambia

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

Phase 3, Observer-blind, Randomized, Active Controlled Trial to Assess the Safety of an Investigational Meningococcal Serogroups ACYWX Conjugate Vaccine (NmCV-5) and Compare Its Immunogenicity to a Licensed Meningococcal Serogroups ACYW Conjugate Vaccine (Menactra®), in Healthy Subjects 2 to 29 Years of Age
Phase 3, Observer-blind, Randomized, Active Controlled Trial to Assess the Safety of an Investigational Meningococcal Serogroups ACYWX Conjugate Vaccine (NmCV-5) and Compare Its Immunogenicity to a Licensed Meningococcal Serogroups ACYW Conjugate Vaccine (Menactra®), in Healthy Subjects 2 to 29 Years of Age
Enrollment Status: Completed
Publish Date: July 27, 2021
Intervention Type: Biological
Study Drugs: NmCV-5, Menactra
Study Phase: Phase 3

8 Total Publications

Safety of the novel oral poliovirus vaccine type 2 (nOPV2) in infants and young children aged 1 to <5 years and lot-to-lot consistency of the immune response to nOPV2 in infants in The Gambia: a phase 3, double-blind, randomised controlled trial.
Safety of the novel oral poliovirus vaccine type 2 (nOPV2) in infants and young children aged 1 to <5 years and lot-to-lot consistency of the immune response to nOPV2 in infants in The Gambia: a phase 3, double-blind, randomised controlled trial.
Journal: Lancet (London, England)
Published: December 02, 2023

Frequently Asked Questions about Ama Umesi

Is Ama Umesi a top-rated expert for Togaviridae Disease?

MediFind is an objective health platform that identifies experts based on real-world data. Ama Umesi is classified as an Experienced expert for Togaviridae Disease, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Ama Umesi participate in research or clinical trials?

Yes. Ama Umesi has published 8 articles and abstracts on conditions like Togaviridae Disease. You can view a list of Ama Umesi's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Umesi's expertise for a condition
ConditionClose
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile